Vaginal clear cell adenocarcinoma in a young woman with a Müllerian duct anomaly and no history of in utero diethylstilbestrol exposure: a fertility-sparing approach

Since most cases of primary vaginal clear cell adenocarcinoma (PVCCA) occur during the reproductive years, it is necessary to evaluate the safety and efficacy of potential fertility-sparing approaches. Herein, the authors report a case of a young woman with a Müllerian duct anomaly and a primary diagnosis of PVCCA without a history of in utero diethylstilbestrol (DES) exposure. She was treated with a fertility-sparing approach involving organ-preserving surgery and oocyte cryopreservation in conjunction with adjuvant pelvic radiotherapy. To date, disease recurrence has not been documented.

Primary vaginal clear cell adenocarcinoma (PVCCA); Müllerian duct anomaly

[1] Hanselaar A., van Loosbroek M., Schuurbiers O., Helmerhorst T., Bulten J., Bernhelm J.: “Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks”. Cancer, 1997, 79, 2229.

[2] Ma L., Benson G.V., Lim H., Dey S.K., Maas R.L.: “Abdominal B (AbdB) Hoxa genes: regulation in adult uterus by estrogen and progesterone and repression in müllerian duct by the synthetic estrogen diethylstilbestrol (DES)”. Dev Biol., 1998, 197, 141.

[3] Smith E.K., White M.C., Weir H.K., Peipins L.A., Thompson T.D.: “Higher incidence of clear cell adenocarcinoma of the cervix and vagina among women born between 1947 and 1971 in the United States”. Cancer Causes Control, 2012, 23, 207.

[4] FIGO Committee on Gynecologic Oncology: “Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia”. Int. J. Gynaecol. Obstet., 2009, 105, 3.

[5] Creasman W.T., Phillips J.L., Menck H.R.: “The National Cancer Data Base report on cancer of the vagina”. Cancer, 1998, 83, 1033.

[6] Dursun P., Doğan N.U., Ayhan A.: “Oncofertility for gynecologic and non-gynecologic cancers: fertility sparing in young women of reproductive age”. Crit. Rev. Oncol. Hematol., 2014, 92, 258.

[7] Venturella R., Lico D., Sarica A., Falbo M.P., Gulletta E., Morelli M., et al.: “OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters”. J. Ovarian Res., 2015, 8, 21.

[8] Cakmak H., Rosen M.P.: “Ovarian stimulation in cancer patients”. Fertil Steril., 2013, 99, 1476.